GlassScriptPhysician profile
Monica P Zeitz
NPI 1710144506
$6,369.28
in general payments reported to CMS, 2019-2025
35 companies · $267 in 2025
The $267 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,221 · 2020: $519 · 2021: $657 · 2022: $880 · 2023: $1,394 · 2024: $1,431 · 2025: $267.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,057 · Education: $34.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,057.41 |
| Education | $34.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,561.79 | 2019-2025 | Linzess, Rinvoq, Viberzi |
| Takeda Pharmaceuticals U.S.A., INC. | $778.30 | 2019-2024 | Entyvio, Gattex, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $705.14 | 2019-2024 | Xifaxan, Trulance, Plenvu |
| Janssen Biotech, INC. | $636.83 | 2019-2025 | Stelara, Tremfya, Simponi |
| Celgene Corporation | $347.66 | 2021-2024 | Zeposia |
| Gilead Sciences, INC. | $333.96 | 2019-2025 | |
| Ferring Pharmaceuticals INC. | $197.13 | 2019-2023 | Rebyota |
| Genzyme Corporation | $187.22 | 2022-2024 | |
| Braintree Laboratories, INC. | $161.30 | 2019-2023 | Suflave |
| Intercept Pharmaceuticals, INC. | $152.17 | 2019-2024 | Ocaliva |
| Pfizer INC. | $142.78 | 2019-2024 | |
| Phathom Pharmaceuticals, INC. | $111.65 | 2024 | Voquezna |
| Ardelyx, INC. | $110.73 | 2024-2025 | Ibsrela |
| Ironwood Pharmaceuticals, INC | $108.31 | 2019-2023 | Linzess |
| Madrigal Pharmaceuticals | $92.01 | 2024-2025 | Resmetirom, Rezdiffra |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $81.83 | 2023-2024 | Dupixent |
| Daiichi Sankyo INC. | $81.46 | 2019-2023 | Injectafer |
| Allergan, INC. | $67.03 | 2019 | |
| Qol Medical, LLC | $65.36 | 2019-2022 | |
| Shionogi INC | $51.59 | 2019 | |
| Evoke Pharma, INC. | $51.51 | 2021-2022 | |
| Ipsen Biopharmaceuticals, INC | $44.04 | 2024-2025 | Bylvay, Iqirvo |
| Novo Nordisk INC | $35.83 | 2024 | Wegovy |
| Alexion Pharmaceuticals, INC. | $33.62 | 2022 | |
| Alfasigma USA, INC. | $30.80 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $25.94 | 2019 | |
| Digestive Care, INC. | $24.01 | 2023 | Pertzye |
| Lilly USA, LLC | $22.43 | 2024 | Omvoh |
| Ucb, INC. | $22.13 | 2019 | |
| Aimmune Therapeutics, INC. | $22.02 | 2024 | |
| Vertex Pharmaceuticals Incorporated | $18.80 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.49 | 2023 | Cyltezo |
| Micro-Tech Endoscopy USA, INC. | $17.60 | 2023 | Lesionhunter |
| Redhill Biopharma INC. | $14.41 | 2021 | |
| Sandoz INC. | $13.40 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Monica Zeitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.